Difference between revisions of "Triptorelin (Trelstar LA)"
Jump to navigation
Jump to search
m (→References) |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[ | + | Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/triptorelin.pdf Triptorelin (Trelstar LA) package insert (locally hosted backup)]</ref> |
<br>Route: IM | <br>Route: IM | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 2000-06-15: Initial FDA approval in the palliative treatment of advanced [[Prostate cancer | prostate cancer]]. ''(Based on Heyns et al. 2003)'' |
| + | ==History of changes in EMA indication== | ||
| + | *1986-03-05: EURD | ||
| + | ==Also known as== | ||
| + | *'''Code names:''' AY-25650, CL-118532 | ||
| + | *'''Generic name:''' triptorelin pamoate | ||
| + | *'''Brand names:''' Decapeptyl, Detryptoreline, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl | ||
| − | |||
| − | |||
==References== | ==References== | ||
<references/> | <references/> | ||
| Line 24: | Line 28: | ||
[[Category:Intramuscular medications]] | [[Category:Intramuscular medications]] | ||
| − | |||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:GnRH agonists]] | [[Category:GnRH agonists]] | ||
| Line 32: | Line 35: | ||
[[Category:FDA approved in 2000]] | [[Category:FDA approved in 2000]] | ||
| + | [[Category:EMA approved in 1986]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 00:07, 6 July 2024
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2000-06-15: Initial FDA approval in the palliative treatment of advanced prostate cancer. (Based on Heyns et al. 2003)
History of changes in EMA indication
- 1986-03-05: EURD
Also known as
- Code names: AY-25650, CL-118532
- Generic name: triptorelin pamoate
- Brand names: Decapeptyl, Detryptoreline, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl